Genetic and pharmacologic inhibition of PKCδ defined its role in oncometabolic processes at the intersection of insulin, IGF and lipid metabolism and validated PKCδ as crucial therapeutic target of the GPM subtype of GBM. The gene discussed is PRKCD; the disease is glioblastoma.